The study found that in patients receiving CDK4/6i, the risks of developing any-grade ILD were doubled and the risk of developing Grade ≥ 3 ILD was tripled compared with controls (Peto odds ratio 2.12 [95% CI 1.57, 2.86], p < 0.00001, and 3.22 [95% CI 1.28, 8.09], p = 0.01, respectively) [32]. Here, CDK4 is linked to interstitial lung disease.